8-K Announcements
3Material company update
Apr 16, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Jan 12, 2026·SEC
Prime Medicine, Inc.(PRME)Earnings, Financials & Key Ratios
PRME•NASDAQ
$3.41
$616M mkt cap·Price updated May 6, 2026
AboutPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$5M+55.3%
- EBITDA-$203M-3.4%
- Net Income-$201M-2.7%
- EPS (Diluted)-1.35+18.3%
- Gross Margin-58.05%-158.1%
- EBITDA Margin-4381.82%+33.4%
- Operating Margin-4498.06%+33.7%
- Net Margin-4342.44%+33.9%
- ROE-146.81%-7.3%
- ROIC-168.27%+35.4%
- Debt/Equity0.96+261.6%
PRME Key Insights
Prime Medicine, Inc. (PRME) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 126.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 25.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRME Price & Volume
Prime Medicine, Inc. (PRME) stock price & volume — 10-year historical chart
Loading chart...
PRME Growth Metrics
Prime Medicine, Inc. (PRME) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-2.32%
3 Years-
TTM55.28%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM18.48%
Return on Capital
10 Years-75.01%
5 Years-72.72%
3 Years-87.58%
Last Year-73.77%
PRME Recent Earnings
Prime Medicine, Inc. (PRME) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 1/12 qtrs (13%)
Q2 2026Latest
Mar 3, 2026EPS
$0.22
Est $0.25
+12.0%
Revenue
$842,000
Est $1M
-34.6%
Q4 2025
Nov 7, 2025EPS
$0.32
Est $0.28
-14.3%
Revenue
$1M
Est $2M
-40.3%
Q3 2025
Aug 7, 2025EPS
$0.41
Est $0.36
-13.9%
Revenue
$1M
Est $3M
-60.2%
Q2 2025
May 8, 2025EPS
$0.40
Est $0.32
-25.0%
Revenue
$1M
Est $2M
-37.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 3, 2026 | $0.22vs $0.25+12.0% | $842,000vs $1M-34.6% |
| Q4 2025 | Nov 7, 2025 | $0.32vs $0.28-14.3% | $1Mvs $2M-40.3% |
| Q3 2025 | Aug 7, 2025 | $0.41vs $0.36-13.9% | $1Mvs $3M-60.2% |
| Q2 2025 | May 8, 2025 | $0.40vs $0.32-25.0% | $1Mvs $2M-37.7% |
Based on last 12 quarters of dataView full earnings history →
PRME Peer Comparison
Prime Medicine, Inc. (PRME) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 KRRO | 125.4M | 13.34 | -1.07 | 181.46% | -18.34% | -115.95% | 0.85 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 SGMO | 37.8M | 0.18 | -0.36 | -67.2% | -331.28% | -8.14% | 1.34 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare PRME vs Peers
Prime Medicine, Inc. (PRME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRME Income Statement
Prime Medicine, Inc. (PRME) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 5.21M | 0 | 0 | 0 | 2.98M | 4.63M |
| Revenue Growth % | - | - | -100% | - | - | - | 55.28% |
| Cost of Goods Sold | 2.76M | 2.98M | 0 | 0 | 0 | 0 | 7.32M |
| COGS % of Revenue | - | 57.2% | - | - | - | - | 158.05% |
| Gross Profit | -2.76M▲ 0% | 2.23M▲ 180.8% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 2.98M▲ 0% | -2.69M▼ 190.1% |
| Gross Margin % | - | 42.8% | - | - | - | 100% | -58.05% |
| Gross Profit Growth % | - | 180.8% | -100% | - | - | - | -190.14% |
| Operating Expenses | 2.17M | 3.16M | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M |
| OpEx % of Revenue | - | 60.69% | - | - | - | 6887.36% | 4440% |
| Selling, General & Admin | 1.25M | 3.16M | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| SG&A % of Revenue | - | 60.69% | - | - | - | 1681.56% | 1130.1% |
| Research & Development | 920K | 2.98M | 70.55M | 86.72M | 147.91M | 155.29M | 160.64M |
| R&D % of Revenue | - | 57.2% | - | - | - | 5205.8% | 3467.96% |
| Other Operating Expenses | 0 | -2.98M | 0 | 0 | 13.5M | 0 | -7.32M |
| Operating Income | -2.17M▲ 0% | -932K▲ 57.1% | -84.47M▼ 8963.7% | -116.54M▼ 38.0% | -204.79M▼ 75.7% | -202.47M▲ 1.1% | -208.35M▼ 2.9% |
| Operating Margin % | - | -17.89% | - | - | - | -6787.36% | -4498.06% |
| Operating Income Growth % | - | 57.09% | -8963.73% | -37.96% | -75.72% | 1.14% | -2.91% |
| EBITDA | 4.34M | -889K | -83.91M | -114.32M | -200.14M | -196.34M | -202.97M |
| EBITDA Margin % | - | -17.06% | - | - | - | -6581.93% | -4381.82% |
| EBITDA Growth % | - | -120.47% | -9338.25% | -36.25% | -75.07% | 1.9% | -3.38% |
| D&A (Non-Cash Add-back) | 6.52M | 43K | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| EBIT | -2.52M | -932K | -84.47M | -116.54M | -191.29M | -202.47M | -201.14M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | -611K | -81.38M | -6.22M | 6.38M | 6.58M | 7.21M |
| Pretax Income | -2.52M▲ 0% | -1.54M▲ 38.9% | -165.85M▼ 10648.7% | -122.77M▲ 26.0% | -198.41M▼ 61.6% | -195.88M▲ 1.3% | -201.14M▼ 2.7% |
| Pretax Margin % | - | -29.62% | - | - | - | -6566.61% | -4342.44% |
| Income Tax | 4K | 1.87M | -486K | -948K | -279K | 0 | 0 |
| Effective Tax Rate % | -0.16% | -121% | 0.29% | 0.77% | 0.14% | 0% | 0% |
| Net Income | -2.53M▲ 0% | -3.41M▼ 34.8% | -165.37M▼ 4749.5% | -121.82M▲ 26.3% | -198.13M▼ 62.6% | -195.88M▲ 1.1% | -201.14M▼ 2.7% |
| Net Margin % | - | -65.45% | - | - | - | -6566.61% | -4342.44% |
| Net Income Growth % | - | -34.84% | -4749.47% | 26.33% | -62.64% | 1.14% | -2.69% |
| Net Income (Continuing) | -2.53M | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M | -201.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.03▲ 0% | -0.05▼ 80.8% | -1.92▼ 3542.6% | -1.46▲ 24.0% | -2.18▼ 49.1% | -1.65▲ 24.2% | -1.35▲ 18.3% |
| EPS Growth % | - | -80.82% | -3542.61% | 24.04% | -49.09% | 24.17% | 18.26% |
| EPS (Basic) | -0.03 | -0.05 | -1.92 | -1.46 | -2.18 | -1.65 | -1.35 |
| Diluted Shares Outstanding | 95.73M | 95.73M | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
| Basic Shares Outstanding | 95.73M | 95.73M | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
PRME Balance Sheet
Prime Medicine, Inc. (PRME) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.7M | 53.4M | 270.58M | 296.62M | 142.98M | 211.89M | 181.29M |
| Cash & Short-Term Investments | 8.65M | 53.33M | 269.62M | 293.92M | 121.67M | 190.44M | 177.68M |
| Cash Only | 8.65M | 36.98M | 185.42M | 187.62M | 41.57M | 182.48M | 63.03M |
| Short-Term Investments | 0 | 16.35M | 84.2M | 106.3M | 80.09M | 7.97M | 114.65M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 50K | 0 | 0 | 246K | 2.25M | 14.67M | 3.61M |
| Total Non-Current Assets | 0 | 1.38M | 31.28M | 63.7M | 50.88M | 85.62M | 161.44M |
| Property, Plant & Equipment | 0 | 596K | 15.68M | 48.55M | 36.6M | 71.56M | 146.75M |
| Fixed Asset Turnover | - | 8.74x | - | - | - | 0.04x | 0.03x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 785K | 15.6M | 15.14M | 14.28M | 14.06M | 14.69M |
| Total Assets | 8.7M▲ 0% | 54.78M▲ 529.9% | 301.86M▲ 451.0% | 360.31M▲ 19.4% | 193.85M▼ 46.2% | 297.51M▲ 53.5% | 342.73M▲ 15.2% |
| Asset Turnover | - | 0.10x | - | - | - | 0.01x | 0.01x |
| Asset Growth % | - | 529.91% | 451% | 19.37% | -46.2% | 53.47% | 15.2% |
| Total Current Liabilities | 7.31M | 19.44M | 57.98M | 26.71M | 56.42M | 37.96M | 37.45M |
| Accounts Payable | 0 | 250K | 1.44M | 4.33M | 19.54M | 11.35M | 8.89M |
| Days Payables Outstanding | - | 30.62 | - | - | - | - | 443.08 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 8.14M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 7.09M | 7.82M |
| Other Current Liabilities | 7.31M | 19.08M | 14.66M | 6.98M | 10.91M | 6.93M | 12.6M |
| Current Ratio | 1.19x | 2.75x | 4.67x | 11.10x | 2.53x | 5.58x | 4.84x |
| Quick Ratio | 1.19x | 2.75x | 4.67x | 11.10x | 2.53x | 5.58x | 4.84x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 1.87M | 4.31M | 17.33M | 4.36M | 106.4M | 184.42M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 108.29M |
| Capital Lease Obligations | 0 | 0 | 3.07M | 17.05M | 4.36M | 37.18M | 0 |
| Deferred Tax Liabilities | 0 | 1.87M | 1.24M | 279K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 6M | 76.13M |
| Total Liabilities | 7.31M | 21.31M | 62.3M | 44.04M | 60.78M | 144.36M | 221.87M |
| Total Debt | 0 | 0 | 10.41M | 28.75M | 13.63M | 40.79M | 116.43M |
| Net Debt | -8.65M | -36.98M | -175.01M | -158.88M | -27.94M | -141.68M | 53.4M |
| Debt / Equity | - | - | 0.04x | 0.09x | 0.10x | 0.27x | 0.96x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.99x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | 1.39M▲ 0% | 33.47M▲ 2309.9% | 239.56M▲ 615.7% | 316.27M▲ 32.0% | 133.07M▼ 57.9% | 153.15M▲ 15.1% | 120.87M▼ 21.1% |
| Equity Growth % | - | 2309.94% | 615.66% | 32.02% | -57.92% | 15.09% | -21.08% |
| Book Value per Share | 0.01 | 0.35 | 2.50 | 3.25 | 1.46 | 1.29 | 0.81 |
| Total Shareholders' Equity | 1.39M | 33.47M | 239.56M | 316.27M | 133.07M | 153.15M | 120.87M |
| Common Stock | 1K | 0 | 0 | 2K | 2K | 2K | 2K |
| Retained Earnings | -2.6M | -6.01M | -171.38M | -293.2M | -491.33M | -687.21M | -888.35M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -27K | -384K | -15K | 1K | 82K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRME Cash Flow Statement
Prime Medicine, Inc. (PRME) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.33M | -5.54M | -34.08M | -131.83M | -165.41M | -122.86M | -162.56M |
| Operating CF Margin % | - | -106.41% | - | - | - | -4118.84% | -3509.59% |
| Operating CF Growth % | - | -315.59% | -514.75% | -286.79% | -25.48% | 25.72% | -32.31% |
| Net Income | -2.53M | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M | -201.14M |
| Depreciation & Amortization | 0 | 43K | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| Stock-Based Compensation | 0 | 391K | 1.75M | 6.46M | 13.91M | 26.07M | 29.27M |
| Deferred Taxes | 0 | 1.87M | -624K | -964K | -279K | 0 | 0 |
| Other Non-Cash Items | 703K | -4.6M | 98.42M | 17.68M | 11.79M | 9.74M | 9.27M |
| Working Capital Changes | 492K | 164K | 31.18M | -35.4M | 2.65M | 31.08M | -5.34M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 250K | 1.19M | 2.46M | 9.14M | -5.26M | 996K |
| Cash from Investing | 0 | -1.06M | -73.63M | -47.1M | 18.71M | 68.46M | -108.76M |
| Capital Expenditures | 0 | -639K | -4.15M | -16.09M | -8.72M | -7.29M | -4.53M |
| CapEx % of Revenue | - | 12.26% | - | - | - | 244.52% | 97.82% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | -423K | -496K | -665K | -170K | 1M | 0 |
| Cash from Financing | 9.98M | 34.93M | 269.28M | 181.49M | 655K | 195.88M | 151.51M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 9.98M | 34.95M | 270.36M | 185.32M | 655K | 170.14M | 139.51M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -20K | -1.09M | -3.82M | 0 | 25.74M | 12M |
| Net Change in Cash | 0▲ 0% | 28.33M▲ 0% | 161.57M▲ 470.4% | 2.57M▼ 98.4% | -146.05M▼ 5780.5% | 141.47M▲ 196.9% | -119.81M▼ 184.7% |
| Free Cash Flow | -1.33M▲ 0% | -6.18M▼ 363.5% | -38.23M▼ 518.3% | -147.92M▼ 286.9% | -174.14M▼ 17.7% | -130.16M▲ 25.3% | -167.09M▼ 28.4% |
| FCF Margin % | - | -118.68% | - | - | - | -4363.36% | -3607.4% |
| FCF Growth % | - | -363.49% | -518.34% | -286.91% | -17.72% | 25.25% | -28.38% |
| FCF per Share | -0.01 | -0.06 | -0.40 | -1.52 | -1.91 | -1.10 | -1.12 |
| FCF Conversion (FCF/Net Income) | 0.53x | 1.63x | 0.21x | 1.08x | 0.83x | 0.63x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 141K | 0 | 0 | 0 |
PRME Key Ratios
Prime Medicine, Inc. (PRME) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -182.07% | -19.56% | -121.13% | -43.83% | -88.19% | -136.88% | -146.81% |
| Return on Invested Capital (ROIC) | - | - | -207.57% | -78.77% | -117.01% | -260.47% | -168.27% |
| Gross Margin | - | 42.8% | - | - | - | 100% | -58.05% |
| Net Margin | - | -65.45% | - | - | - | -6566.61% | -4342.44% |
| Debt / Equity | - | - | 0.04x | 0.09x | 0.10x | 0.27x | 0.96x |
| FCF Conversion | 0.53x | 1.63x | 0.21x | 1.08x | 0.83x | 0.63x | 0.81x |
| Revenue Growth | - | - | -100% | - | - | - | 55.28% |
PRME SEC Filings & Documents
Prime Medicine, Inc. (PRME) SEC filings — annual & quarterly reports (10-K, 10-Q)
10-K Annual Reports
1FY 2026
Mar 3, 2026·SEC
PRME Frequently Asked Questions
Prime Medicine, Inc. (PRME) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prime Medicine, Inc. (PRME) reported $4.6M in revenue for fiscal year 2025.
Prime Medicine, Inc. (PRME) grew revenue by 55.3% over the past year. This is strong growth.
Prime Medicine, Inc. (PRME) reported a net loss of $201.1M for fiscal year 2025.
Dividend & Returns
Prime Medicine, Inc. (PRME) has a return on equity (ROE) of -146.8%. Negative ROE indicates the company is unprofitable.
Prime Medicine, Inc. (PRME) had negative free cash flow of $167.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More PRME
Prime Medicine, Inc. (PRME) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates